The recent Review article by Astronomo and Burton (Carbohydrate vaccines: developing sweet solutions to sticky situations. Nature Rev. Drug Discov. 9, 308–324 (2010))1 highlighted advances in the use of glycoconjugate vaccines for protection against infection with encapsulated bacteria such as Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae type b. The 23-valent pneumococcal polysaccharide vaccine (Pneumovax (PPS); Merck) has been used for many years in adults or children <2 years of age2. However, this vaccine is considered to be poorly immunogenic in young children and the introduction of the seven-valent pneumococcal conjugate vaccine (Prevnar (PCV7); Wyeth/Pfizer) has had a profound impact on vaccine-type invasive pneumococcal disease in children <2 years of age, with vaccine efficacy estimated to be between 77% and 97.4% based on the pivotal trials conducted in populations from the Northern California Kaiser Permanente, Navajo and White Mountain Apache, South African, and Gambian regions3. The success of these vaccines is attributed to the conjugation of protein carriers (for example, CRM197 and tetanus toxoid) to pneumococcal polysaccharides, which significantly enhances vaccine immunogenicity in this age group4.
In their article, Astronomo and Burton suggest that for the evaluation of new carbohydrate-based vaccines, functional end points may be more useful than enzyme-linked immunosorbent assay (ELISA) titres. Studies with pneumococcal conjugate vaccines have generally supported this conclusion. There have been several instances in which clinical outcomes with pneumococcal vaccines have correlated with opsonophagocytic activity (OPA) — which is presumably the protective mechanism of anticapsule antibodies — but not with ELISA titres. For instance, pneumococcal polysaccharide immunization is not as protective in elderly adults compared with young adults despite similar serotype-specific immunoglobulin G (IgG) titres measured by ELISA. Yet, when OPA responses were studied in these subjects, young adults showed better functional responses than elderly adults5. Similarly, poor cross-protection against serotype 19A by PCV7 was not predicted by ELISA IgG titres but was predicted by OPA outcomes6,7,8.
Nevertheless, pneumococcal vaccine studies have also revealed many instances in which ELISA titres were highly correlated with OPA results and were useful in predicting clinical outcomes following vaccination. Studies suggest that ELISA or OPA measures of PCV7 vaccine responses in young children are largely comparable. These studies have led to the conclusion that a serotype-specific IgG concentration of 0.35 μg per ml provides a useful threshold for measuring the efficacy of PCV7 in infancy using a WHO (World Health Organization)-defined ELISA9. In a randomized controlled pneumococcal vaccine trial in Fiji, we have recently found a strong correlation between ELISA IgG and OPA titres for PCV7 serotypes, particularly following booster immunization with pneumococcal polysaccharides, with correlation coefficients increasing above that observed following primary PCV7 series10,11,12,13,14,15 (Fig. 1). These data suggest that ELISA IgG titres can be regarded as a suitable correlate of vaccine-induced immune protection in young children.
Owing to a long history of development and standardization, the WHO-defined ELISA is currently widely accepted for the evaluation of pneumococcal vaccine immunogenicity. By contrast, OPAfor the functional evaluation of pneumococcal antibodies remains less standardized than the ELISA, although significant efforts towards validation of OPA are ongoing. The ELISA is a robust immunoassay that can be readily replicated in many different laboratories. Furthermore, novel approaches using multiplex technology offer considerably improved efficiency for the ELISA approach. Thus, although we support the use of functional assays for the evaluation of vaccine immunogenicity in clinical studies, we believe that the standard ELISA is and will continue to be important in evaluating vaccine immunogenicity in many situations.
Astronomo, R. D. & Burton, D. R. Carbohydrate vaccines: developing sweet solutions to sticky situations? Nature Rev. Drug Discov. 9, 308–324 (2010).
O'Brien, K. L., Hochman, M. & Goldblatt, D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect. Dis. 7, 597–606 (2007).
Lucero, M. G. et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst. Rev. CD004977 (2009).
Makela, P. H. Conjugate vaccines — a breakthrough in vaccine development. Southeast Asian J. Trop. Med. Public Health 34, 249–53 (2003).
Schenkein, J. G., Park, S. & Nahm, M. H. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine 26, 5521–5526 (2008).
Yu, X. et al. Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants. J. Infect. Dis. 180, 1569–1576 (1999).
Lee, H., Nahm, M. H., Burton, R. & Kim, K. H. Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A. Clin. Vaccine Immunol. 16, 376–381 (2009).
Fernsten, P., Hu, B. & Yu, X. Specificity of the opsonic response to serotype 19A and 19F conjugate vaccines. ISPPD-6, Abstr. P3–065 (2008).
Paradiso, P. Essential criteria for evaluation of pneumococcal conjugate vaccine candidates. Vaccine 27 (Suppl. 3), C15–C18 (2009).
Russell, F. M. et al. Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine. Vaccine 27, 5685–5691 (2009).
Russell, F. M. et al. Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy. Vaccine 28, 3086–3094 (2010).
Russell, F. M. et al. Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age. Vaccine 29, 535-544 (2011).
Balloch, A., Licciardi, P. V., Russell, F. M., Mulholland, E. K. & Tang, M. L. Infants aged 12 months can mount adequate serotype-specific IgG responses to pneumococcal polysaccharide vaccine. J. Allergy Clin. Immunol. 126, 395–397 (2010).
Balloch, A. et al. Does serotype-specific IgG and avidity to Streptococcus pneumoniae following infant immunisation correlate with functional opsonophagocytic activity? ISPPD-6, Abstr. P3-011 (2008).
Balloch, A. et al. Can serotype-specific IgG predict the functional OPA response? ISPPD-7, Abstr. 152 (2010).
The authors declare no competing financial interests.
About this article
Cite this article
Licciardi, P., Balloch, A., Russell, F. et al. Pneumococcal glycoconjugate vaccines produce antibody responses that strongly correlate with function. Nat Rev Drug Discov 10, 393 (2011) doi:10.1038/nrd3012-c1
Journal of Allergy and Clinical Immunology (2012)